Back to search

University of Leeds

Production and purification of recombinant amelogenins for investigating proteopathic mechanisms associated with amelogenesis imperfecta

Abstract

dc:description.abstract

In a mouse model of amelogenesis imperfecta (Al), an amelogenin p.Y64H mutation was reported to cause the abnormal retention of amelogenin in the ameloblast secretory pathway. This was hypothesised to be due to enhanced pathological aggregation of mutant amelogenin. The aim of this thesis was to develop purification methodologies to deliver large amounts of wild-type (WT) and mutant recombinant amelogenins (r-amelogenins) and develop microplate based binding assays to study protein-protein interactions of these recombinants to elucidate the effect of the mutation on aggregation. His-tagged r-amelogenin was extracted from Escherichia coli (E. Coli) with 3% acetic acid. This extract was subject to nickel affinity chromatography (targeting the His-tag); the 'gold standard' technique for purifying recombinant proteins from bacterial contaminants. The His-tag was then removed but cleavage was only ~50% efficient. Cleaved r-amelogenin unexpectedly still bound the nickel column (presumably due to the presence of di and tri histidine motifs in the amelogenin sequence) which precluded its isolation from uncleaved contaminant. Size exclusion chromatography was also trialled and also found to be ineffective. Finally, preparative SOS PAGE was found to produce cleaved r-amelogenin at single band purity on analytical SOS PAGE. After optimising the purification regime, simple and cost-effective microplate binding assays were developed initially using amelogenin rich porcine enamel matrix derivative (EMD) as a surrogate. Initially the aim was to immobilise EMD on the plate and then measure the binding of FITC-labelled EMD by simple end point fluorescence measurements. An alternative method trialled UV spectrophotometry to monitor the loss of EMD from free solution in real time as it bound EMD immobilised to the well surfaces. This latter method provided an adaptable, simple and cost-effective means of monitoring amelogenin binding and aggregation. It provided pilot data suggesting that p.Y64H mutant r-amelogenin was clearly more aggregative than WT r-amelogenin.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Leeds
Year dc:date.issued
2018

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Gabe, Claire Madialin
Advisors dc:contributor.advisor
  • Brookes, Steven J.
  • Kirkham, Jennifer

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.770049
Dc Identifier Grantnumber
Grant no. 075945

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Gabe, Claire Madialin. Production and purification of recombinant amelogenins for investigating proteopathic mechanisms associated with amelogenesis imperfecta. doctoral thesis, University of Leeds, 2018.